Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 9/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31435957 | 0.90 | PTGDR2 (0.33) | ELANEGSK3AGSK3BPCSK9PTGDR2 | |
| SCHEMBL31435956 | 0.83 | ELANE (0.36) | ELANEGRIN1GRIN2BPCSK9PTGDR2 | |
| SCHEMBL31435958 | 0.81 | DGAT1 (0.33) | GSK3AGSK3B | |
| SCHEMBL31435987 | 0.81 | PTPN11 (0.43) | ELANEGRIN1GRIN2BAAK1 | |
| SCHEMBL31435946 | 0.78 | PTGS2 (0.35) | ELANEPTGDR2 | |
| SCHEMBL31396578 | 0.72 | PTGDR2 (0.37) | PCSK9PTGDR2 | |
| SCHEMBL31396525 | 0.71 | MAPT (0.35) | ELANEGRIN1GRIN2BPTGDR2 | |
| SCHEMBL31396543 | 0.70 | PTGDR2 (0.34) | PCSK9PTGDR2 | |
| SCHEMBL31436019 | 0.69 | PTPN11 (0.46) | — | |
| SCHEMBL31396558 | 0.69 | PTGS1 (0.35) | PCSK9PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2025-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | TYRO3, TH, TYR | ELANE 3500/4885GSK3A 402/4885GSK3B 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.